LabCorp’s Covance Drug Development segment is set to acquire Envigo’s non-clinical research services business, while Envigo’s Research Models Services business will purchase the Covance Research Products business.
LabCorp said that the proposed deals will make the company to pay a net cash of $485m and will add an incremental $156m to revenues on a pro forma 2018 basis.
The deal will allow Envigo to become a pure-play research models and services business, while Covance to expand its global non-clinical drug development capabilities.
LabCorp chairman and CEO David King said: “This unique transaction is part of our strategy to transform drug development, strengthening Covance’s ability to offer comprehensive global non-clinical research services to the biopharma industry.”
The scientific and technical expertise and industry insight of Envigo will help Covance to advance its non-clinical capabilities. Covance facilities in Europe and the US will also allow LabCorp to meet growing requirements of the clients.
The combined Covance non-clinical research business will increase its employee base by nearly one-third, to around 4,200 employees across the globe.
The combined research models and services of both suppliers will allow clients to access best models for their research needs across biopharma, contract research organization industry, government and academia.
Envigo, which is a new branded business, will employ over 1,200 people across the globe.
Via strategic supply agreement, the new Envigo research models and services business and Covance will continue to provide research models and services, as well as full range of models, diets and bedding to the clients.
Subject to labor consultations, regulatory approvals and customary closing conditions, the proposed transactions are expected to be completed within two months.
Envigo president and CEO Dr Adrian Hardy said: “This landmark agreement will provide an enhanced experience to our valued customers across both segments of our company and closely aligns with our vision to work together to build a healthier and safer world.”
LabCorp provides comprehensive clinical laboratory and end-to-end drug development services, while Envigo offers mission-critical products and research services for biopharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations.
Source: PBR
The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months.
RSV, or respiratory syncytial virus, has long been a top target for vaccine developers. While companies have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.
By monitoring which areas of the brain responded to localized electrical stimulation, scientists from the Google Research Brain Team and Mayo Clinic developed an artificial intelligence algorithm to map out the structure of brain networks.
